JP2001515712A5 - - Google Patents

Download PDF

Info

Publication number
JP2001515712A5
JP2001515712A5 JP2000510770A JP2000510770A JP2001515712A5 JP 2001515712 A5 JP2001515712 A5 JP 2001515712A5 JP 2000510770 A JP2000510770 A JP 2000510770A JP 2000510770 A JP2000510770 A JP 2000510770A JP 2001515712 A5 JP2001515712 A5 JP 2001515712A5
Authority
JP
Japan
Prior art keywords
april
use according
blocking agent
suppressing
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000510770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/019191 external-priority patent/WO1999012965A2/en
Publication of JP2001515712A publication Critical patent/JP2001515712A/ja
Publication of JP2001515712A5 publication Critical patent/JP2001515712A5/ja
Pending legal-status Critical Current

Links

JP2000510770A 1997-09-12 1998-09-11 増殖効果を有する新規タンパク質−april Pending JP2001515712A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US60/058,786 1997-09-12
US7938498P 1998-03-26 1998-03-26
US60/079,384 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (2)

Publication Number Publication Date
JP2001515712A JP2001515712A (ja) 2001-09-25
JP2001515712A5 true JP2001515712A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510770A Pending JP2001515712A (ja) 1997-09-12 1998-09-11 増殖効果を有する新規タンパク質−april

Country Status (20)

Country Link
US (3) US20030138884A1 (cg-RX-API-DMAC7.html)
EP (1) EP1027431A2 (cg-RX-API-DMAC7.html)
JP (1) JP2001515712A (cg-RX-API-DMAC7.html)
KR (1) KR100618492B1 (cg-RX-API-DMAC7.html)
CN (1) CN1195849C (cg-RX-API-DMAC7.html)
AU (1) AU759717B2 (cg-RX-API-DMAC7.html)
BR (1) BR9812634A (cg-RX-API-DMAC7.html)
CA (1) CA2303615A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ294615B6 (cg-RX-API-DMAC7.html)
EA (1) EA005411B1 (cg-RX-API-DMAC7.html)
EE (1) EE200000147A (cg-RX-API-DMAC7.html)
HU (1) HUP0004611A3 (cg-RX-API-DMAC7.html)
IL (1) IL134537A0 (cg-RX-API-DMAC7.html)
IS (1) IS5378A (cg-RX-API-DMAC7.html)
NO (1) NO20001242L (cg-RX-API-DMAC7.html)
NZ (1) NZ503850A (cg-RX-API-DMAC7.html)
PL (1) PL339463A1 (cg-RX-API-DMAC7.html)
SK (1) SK3542000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200000669T2 (cg-RX-API-DMAC7.html)
WO (1) WO1999012965A2 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6440694B1 (en) * 1997-09-30 2002-08-27 Pharmacia & Upjohn Company TNF-related death ligand
WO1999026976A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
CZ299819B6 (cs) 1999-01-25 2008-12-03 Biogen Idec Ma Inc. Farmaceutické kompozice obsahující protilátky specifické pro rozpustný BAFF
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
HK1043608B (en) * 1999-08-17 2007-12-07 Biogen Ma Inc. Baff receptor (bcma), an immunoregulatory agent
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP1259544B1 (en) 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologous polypeptide of the tnf family
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
AU2001263114A1 (en) * 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1294949A4 (en) * 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
US7189820B2 (en) 2001-05-24 2007-03-13 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (APRIL)
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
EP1608730B1 (en) 2003-03-28 2013-11-06 Biogen Idec MA Inc. Truncated baff receptors
WO2005075511A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
KR20080056714A (ko) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법
CA2623530C (en) 2005-09-26 2015-02-03 Apotech Corporation Antibodies against april as biomarkers for early prognosis of lymphoma patients
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007134326A2 (en) 2006-05-15 2007-11-22 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
WO2010100056A2 (en) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
EP2542679A1 (en) * 2010-03-05 2013-01-09 Academisch Medisch Centrum bij de Universiteit van Amsterdam B-cell stimulating fusion proteins of an antigen with baff or april
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
HRP20231121T1 (hr) * 2013-09-23 2023-12-22 Regeneron Pharmaceuticals, Inc. Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US20150143559A1 (en) * 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
JP2023548866A (ja) 2020-10-29 2023-11-21 インダストリアル ポリマーズ アンド ケミカルズ, インコーポレイテッド 病原体監視及び不活性化のエアフィルター
CA3228678A1 (en) 2021-08-11 2023-02-16 Amato J. Giaccia Methods of reducing production of iga, igm and/or igg using sbcma variants and fc fusion proteins thereof
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記55有限公司 Cd19/cd38多特異性抗體
CN118909083A (zh) * 2024-07-30 2024-11-08 江苏省农业科学院 一种猪b细胞增殖诱导配体蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
DE69630710T2 (de) * 1996-03-14 2004-09-23 Human Genome Sciences Inc. Humaner tumornekrosefaktor delta und epsilon
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Similar Documents

Publication Publication Date Title
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
PL287844A1 (en) Method of obtaining an oraly administered composite medicine for treating interstinal inflamatory diseases
HK1043313A1 (zh) 用於治疗癌症的多西他赛和rhumab her2
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
CA2334267A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
CA2214503A1 (en) Method for treating tumors
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
JP2004537500A5 (cg-RX-API-DMAC7.html)
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
WO2000008007A3 (de) Cyclopentabenzofuran-derivate und ihre verwendung
JP2002530353A5 (cg-RX-API-DMAC7.html)
Zein Interferons in the management of viral hepatitis
EP1561462A3 (en) Anti arrhytmic composition and methods of treatment
AU3401093A (en) Therapeutic agent for threatened abortion
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
Corazziari Need of the ideal drug for the treatment of chronic constipation
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
WO2001045642A3 (en) Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease
JP2002520292A5 (ja) ヒト成長因子と組み合わせた脈管形成剤としてのコンポーネントbの使用